Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming, with a mission to establish new equilibriums that solve complex diseases. They are dedicated to saving lives everywhere by spreading the immuno-balance paradigm. Their innovative Allocetra™ cell-based therapy breaks old paradigms and offers a radically different clinical approach to treating numerous acute conditions.

Enlivex's drug pipeline is focused on macrophage reprogramming in solid cancers, sepsis, and other indications. With a short regulatory approval pathway and FDA & EU orphan designations, they are well-positioned for post-Phase II marketing approval. Enlivex boasts a strong leadership team, inspired by great science and a sense of mission.

Their management, clinical advisors, personnel, and affiliates have extensive knowledge in the research and development of therapies based on macrophage reprogramming. Enlivex is committed to transforming the landscape of healthcare through their innovative approaches to disease treatment